CTOs on the Move

MiRagen

www.miragen.com

 
miRagen Therapeutics is a biotechnology company advancing new treatments for patients with diseases that are underserved by today’s therapies.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.miragen.com
  • 6200 Lookout Road
    Boulder, CO USA 80301
  • Phone: 720.643.5200

Executives

Name Title Contact Details

Funding

MiRagen raised $90.9M on 11/06/2020

Similar Companies

ArQule, Inc.

ArQule, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

ActaCell

ActaCell is a Austin, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Omniome

Based in San Diego and founded in 2013, Omniome is a biotechnology company developing a proprietary DNA sequencing platform capable of delivering unsurpassed sequencing accuracy. Backed by leading life sciences venture investors and a proven management team, Omniome`s vision is to be the most trusted DNA sequencing platform and leader in clinical sequencing. We are a quality-focused, start-up environment where development thrives. Our culture is inspiring, fun and consists of a talented team of individuals who propose innovative ideas keeping collaboration a top priority.

ZYTO Corporation

ZYTO Corporation is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Spring Bank Pharmaceuticals

Spring Bank Pharmaceuticals (NASDAQ: SBPH) is a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics using our proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform. SMNH compounds are small segments of nucleic acids that the company designs to selectively target and modulate the activity of specific proteins implicated in various disease states. Spring Bank is developing its most advanced SMNH product candidate, inarigivir soproxil (formerly referred to as SB 9200), for the treatment of viral diseases, including hepatitis B virus (HBV), and other SMNH product candidates, including SB 11285, the company`s lead immunotherapeutic agent for the treatment of selected cancers through the activation of the STimulator of Interferon Genes, or STING, pathway.